Here are 3 ASX biotech shares with blockbuster growth potential

I think the Australian share market is home to a number of exciting biotech shares and none more so than $56 billion biotech-giant CSL Limited (ASX: CSL). In my opinion CSL is easily one of the highest quality businesses on the ASX and a fantastic buy and hold investment.

But it isn’t the only biotech share worth taking a closer look at. Whilst it may be a touch too soon for an investment, here are three growing biotech shares that I think should be on investor’s watch lists:

Bionomics Ltd (ASX: BNO)

It has been a great 12 months for shareholders of this explosive biotech company. Since this time last year its share price has climbed 25%. Investors appear to be optimistic that the company is onto a winner with its BNC210 drug. The drug has been designed to treat Generalized Anxiety Disorder, a market estimated by the company to be worth up to US$18.2 billion by 2020. Whilst it is early days, recent trials have been very encouraging. It has outperformed the current standard of care Lorazepam without any signs of sedation, memory impairment, addiction, or loss of motor co-ordination.

Cynata Therapeutics Ltd (ASX: CYP)

Cynata is an exciting stem cell and regenerative medicine company with the ability to produce an unlimited number of stem cells at a low cost through its Cymerus technology. Japan-based Fujifilm recently bought a 10% stake in the company as part of its push to become a world leader in stem cell supply and technology. As a result, the two parties will collaborate on the further development and commercialisation of its therapeutic MSC product CYP-001. This product will be used to treat graft-versus-host-disease. Fujifilm has the option to an exclusive worldwide license to market and sell the product in the future. Definitely one to keep a close eye on in my opinion.

Opthea Ltd (ASX: OPT)

Opthea is a developer of novel biologic therapies for the treatment of eye diseases. In the last 12 months the Opthea share price has risen an astonishing 120% thanks largely to the progress the company has made with its leading drug candidate OPT-302. The novel trap therapy is used for the treatment of wet age-related macular degeneration. Whilst a commercial launch is still some way off, clinical trials have been positive thus far. In fact, just today the company announced that it has received positive feedback from European regulatory agencies. A phase 1/2A clinical trial of 51 patients with wet AMD is expected to conclude by the end of the month.

If you're looking for shares to buy immediately then look no further than these fast-growing shares. I believe each is positioned to deliver a stunning FY 2017, which could make it an opportune time to invest.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often full franked..

But knowing which blue chips to buy, and when, can often be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.